Market Rating: SunTrust Says Its Time To Downgrade Juno Therapeutics (NASDAQ:JUNO)

November 25, 2016 - By whatsonthorold

Market Rating:  SunTrust Says Its Time To Downgrade Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) Downgrade

SunTrust decreased Juno Therapeutics (NASDAQ:JUNO)‘s stock to a Hold rating from Buy. The ratings change was made public in a a note today. The firm from today has a $25 target on the stock.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 108.78% above today’s ($22.56) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by FBR Capital on Friday, July 8. As per Friday, July 8, the company rating was downgraded by JP Morgan. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 18. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Outperform” rating given on Thursday, June 2 by Raymond James. As per Tuesday, December 15, the company rating was upgraded by Standpoint Research. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by Northland Capital on Wednesday, July 22. The stock has “Buy” rating given by Suntrust Robinson on Friday, January 29. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, August 5. Maxim Group has “Buy” rating and $50 price target. The rating was maintained by Maxim Group on Wednesday, November 23 with “Buy”. The company was initiated on Monday, August 24 by Standpoint Research.

The stock decreased 24.50% or $7.32 during the last trading session, hitting $22.56. About 331 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 EPS, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio is positive, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.

Price T Rowe Assoc Md has 23,600 shares for 0% of their US portfolio. Moreover, Parametrica Mgmt Limited has 0.67% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 11,609 shares. Rhumbline Advisers has 0.01% invested in the company for 55,351 shares. Checchi Capital Advisers Limited Company has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Mycio Wealth Partners Ltd holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 500 shares. Swiss Bancshares holds 79,900 shares or 0% of its portfolio. Ibm Retirement Fund accumulated 6,342 shares or 0.01% of the stock. The Pennsylvania-based Brick & Kyle Assoc has invested 0.02% in Juno Therapeutics Inc (NASDAQ:JUNO). Ameriprise Fincl last reported 383,023 shares in the company. Moreover, Winfield Assocs has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 20 shares. Schwab Charles Inv Management has 0.01% invested in the company for 234,448 shares. Trust Of Vermont, a Vermont-based fund reported 145 shares. State Street accumulated 1.66 million shares or 0.01% of the stock. Suffolk Capital Management Limited has invested 0.32% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Thompson Davis & last reported 0.11% of its portfolio in the stock.

Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $1.80 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” with publication date: November 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>